Results 51 to 60 of about 17,963 (297)
Journal of Clinical Endocrinology and Metabolism, 2019 Context The improved remission and complication rates of current transsphenoidal surgery warrant reappraisal of the position of surgery as a viable alternative to dopamine agonists in the treatment algorithm of prolactinomas.
A. Z. Najafabadi +10 more
semanticscholar +1 more source
Anti-c-myc efficacy block EGFL7 induced prolactinoma tumorigenesis
Open Chemistry, 2019 Resistance to Dopamine agonists therapy is still a key factor that hinders the clinical treatment of prolactinoma. Consequently, a large number of investigations have been carried out to identify novel therapeutic targets.
Lan Xiaolei +4 more
doaj +1 more source
The value of PRL in predicting prolactinοma in hyperprolactinemic PCOS [PDF]
, 2018 Background To identify a serum prolactin (PRL) cut‐off value indicative of a PRL‐producing adenoma in women with Polycystic Ovarian Syndrome (PCOS) and hyperprolactinemia and characterize such patients.
Angelousi, Anna +7 more
core +1 more source
Management of Dopamine Agonist-Resistant Prolactinoma
Neuroendocrinology, 2019 Dopamine agonists are usually very effective in the treatment of prolactinomas. Nonetheless, a subset of individuals does not respond satisfactorily to these agents, and this resistance is characterized by failure to achieve normoprolactinemia and a 30 ...
D. Maiter
semanticscholar +1 more source
Late presentation of acromegaly in medically controlled prolactinoma patients
Endocrinology, Diabetes & Metabolism Case Reports, 2016 Co-secretion of growth hormone (GH) and prolactin (PRL) from a single pituitary adenoma is common. In fact, up to 25% of patients with acromegaly may have PRL co-secretion.
Ekaterina Manuylova +6 more
doaj +1 more source
Relationship between prolactin plasma levels and white matter volume in women with multiple sclerosis [PDF]
, 2015 BACKGROUND: The role of prolactin (PRL) on tissue injury and repair mechanisms in multiple sclerosis (MS) remains unclear. The aim of this work was to investigate the relationship between PRL plasma levels and brain damage as measured by magnetic ...
Barletta, VALERIA TERESA +10 more
core +4 more sources
Annals of Medicine, 1998 The objectives of the treatment of hyperprolactinaemia are to suppress excessive hormone secretion and its clinical consequences, to remove tumour mass, to preserve the residual pituitary function and to prevent disease recurrence or progression. Prior to the advent of pharmacotherapy, therapy usually consisted of surgical resection and/or pituitary ...
COLAO, ANNAMARIA +2 more
openaire +4 more sources
The birth and rise of a craniopharyngioma: the radiological evolution of an incidental craniopharyngioma detected on serial MRI during medical treatment of a macroprolactinoma [PDF]
, 2016 This case demonstrates the rare coexistence of a prolactinoma with craniopharyngioma and documents its radiological growth. This case suggests that patients with pituitary neoplasms should be followed closely and although prolactinomas can often be ...
Losa, Marco +3 more
core +1 more source
Predictors of the Response to Dopaminergic Therapy in Patients with Prolactinoma.
Journal of Clinical Endocrinology and Metabolism, 2020 PURPOSE Withdrawal of dopamine agonist (DA) therapy in patients with prolactinoma who are controlled by a small dose of medication is recommended by several guidelines.
Camille Hage, R. Salvatori
semanticscholar +1 more source
AIMS Neuroscience, 2021 Pituitary prolactinoma is one of the most complicated and fatally pathogenic pituitary adenomas. Therefore, there is an urgent need to improve our understanding of the underlying molecular mechanism that drives the initiation, progression, and metastasis
Vikrant Ghatnatti +4 more
doaj +1 more source